DE69941775D1 - Hämoglobin-polysaccharid-konjugate - Google Patents

Hämoglobin-polysaccharid-konjugate

Info

Publication number
DE69941775D1
DE69941775D1 DE69941775T DE69941775T DE69941775D1 DE 69941775 D1 DE69941775 D1 DE 69941775D1 DE 69941775 T DE69941775 T DE 69941775T DE 69941775 T DE69941775 T DE 69941775T DE 69941775 D1 DE69941775 D1 DE 69941775D1
Authority
DE
Germany
Prior art keywords
hemoglobin
polysaccharide conjugates
polysaccharide
conjugate
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941775T
Other languages
English (en)
Inventor
Gordon W Adamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapure Biopharma Inc
Original Assignee
Therapure Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapure Biopharma Inc filed Critical Therapure Biopharma Inc
Application granted granted Critical
Publication of DE69941775D1 publication Critical patent/DE69941775D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
DE69941775T 1998-03-31 1999-03-25 Hämoglobin-polysaccharid-konjugate Expired - Lifetime DE69941775D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002233725A CA2233725A1 (en) 1998-03-31 1998-03-31 Hemoglobin-hydroxyethyl starch complexes
PCT/CA1999/000260 WO1999049897A1 (en) 1998-03-31 1999-03-25 Hemoglobin-polysaccharide conjugates

Publications (1)

Publication Number Publication Date
DE69941775D1 true DE69941775D1 (de) 2010-01-21

Family

ID=4162275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941775T Expired - Lifetime DE69941775D1 (de) 1998-03-31 1999-03-25 Hämoglobin-polysaccharid-konjugate

Country Status (12)

Country Link
US (2) US6500930B2 (de)
EP (1) EP1066057B1 (de)
JP (1) JP4674289B2 (de)
CN (1) CN1191864C (de)
AT (1) ATE451125T1 (de)
AU (1) AU759595B2 (de)
CA (1) CA2233725A1 (de)
DE (1) DE69941775D1 (de)
ES (1) ES2336053T3 (de)
NZ (1) NZ507383A (de)
RU (1) RU2225222C2 (de)
WO (1) WO1999049897A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404111C (en) * 2000-03-21 2010-05-25 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag A polysaccharide-polypeptide conjugate
US6956119B2 (en) 2000-03-21 2005-10-18 Hans Loibner Polysaccharide-polypeptide conjugate
CA2319966A1 (en) * 2000-09-19 2002-03-19 Dextro-Sang Corporation Improved dextran-hemoglobin conjugate as potential blood substitute
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
WO2004024776A1 (en) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1653991A2 (de) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Durch oxime als bindungsgruppe verbundene konjugate eines polymers mit einem protein
PL1660134T3 (pl) * 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
CN102302787A (zh) * 2004-03-11 2012-01-04 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
WO2005092928A1 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
US7172906B2 (en) * 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
EP2899277A1 (de) 2004-11-26 2015-07-29 Pieris AG Verbindung mit Affinität für das zytotoxische T-Lymphozyten-assoziierte Antigen (CTLA-4)
KR20150061019A (ko) * 2005-04-08 2015-06-03 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
CN101443044A (zh) * 2005-09-22 2009-05-27 哈达斯特医学研究服务与开发有限公司 治疗活性化合物的葡聚糖和阿拉伯半乳聚糖结合物
MX2009004447A (es) * 2006-10-24 2009-10-08 Rna Holding B V Inmovilizacion y aplicacion de carbohidratos antigenicos para detectar microorganismos infecciosos.
CN101199856B (zh) * 2006-12-15 2011-04-20 天津协和生物科技发展有限公司 一种携氧抗休克药物
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
EP2070951A1 (de) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
BRPI0915508B1 (pt) 2008-07-09 2019-11-19 Melaleuca Inc complexo de polissacarídeos de mineral-aminoácido, processo para preparar o referido complexo, e composição compreendendo dois ou mais dos referidos compostos
CN106139123A (zh) 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
EP3660510A3 (de) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteine von humanem lipocalin 2 (lcn2, hngal) mit affinität für ein bestimmtes zielmolekül
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
WO2012022742A1 (en) 2010-08-16 2012-02-23 Pieris Ag Binding proteins for hepcidin
JP6100694B2 (ja) 2010-11-15 2017-03-22 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
CN102871985B (zh) * 2011-07-13 2014-03-12 中国科学院化学研究所 一种血红蛋白微胶囊血液代用品及其制备方法
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
RU2497828C1 (ru) * 2012-06-22 2013-11-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Химии Коми Научного Центра Уральского Отделения Российской Академии Наук Гидрофильный конъюгат гидроксиэтилкрахмала и 2,6-диизоборнил-4-метилфенола
EP3441400B1 (de) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Neuartige polypeptide mit spezifischer bindung und verwendungen davon
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
CN105246503A (zh) 2013-03-14 2016-01-13 第一三共株式会社 Pcsk9的新颖结合蛋白
CA2936611A1 (en) 2014-01-13 2015-07-16 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
BR112016027024A2 (pt) 2014-05-22 2017-10-31 Pieris Pharmaceuticals Gmbh polipeptídeos de ligação específica e seus usos
US10526382B2 (en) 2015-01-28 2020-01-07 Pieris Pharmaceuticals Gmbh Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof
AU2016221816B2 (en) 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US11261221B2 (en) 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
CN108112253B (zh) 2015-05-18 2022-09-23 皮里斯制药有限公司 抗癌融合多肽
EP3115371A1 (de) 2015-07-07 2017-01-11 Sanofi Fusionsmoleküle
EA201890198A1 (ru) 2015-07-15 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфичные в отношении lag-3
JP7025021B2 (ja) * 2015-10-26 2022-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 還元多糖および酸化多糖ならびにそれらの使用の方法
BR112018010887A2 (pt) 2015-11-30 2018-11-21 Pieris Australia Pty Ltd polipeptídeo de fusão
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3571219A1 (de) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin-muteine mit bindungsaffinität für lag-3
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
HRP20230590T2 (hr) 2018-07-31 2024-02-16 Pieris Pharmaceuticals Gmbh Novi fuzijski protein specifičan za cd137 i pd-l1
CN113474359A (zh) 2019-02-26 2021-10-01 皮里斯制药有限公司 对cd137和gpc3特异性的新型融合蛋白
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제
AU2022253567A1 (en) 2021-04-08 2023-11-23 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
CN114617957B (zh) * 2022-03-10 2024-01-16 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925344A (en) 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
CA1055932A (en) * 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) * 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
FR2640141B1 (fr) * 1988-12-14 1993-04-16 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
WO1991015215A1 (en) * 1990-03-30 1991-10-17 Biomedical Frontiers, Inc. Fluid resuscitation
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
NZ262349A (en) 1993-03-16 1996-05-28 Hemosol Inc Chemically modifying haemoglobin by crosslinking with a polyaldehyde produced by ring opening oxidation of a saccharide; for use in a blood substitute
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5529719A (en) 1995-03-27 1996-06-25 Xerox Corporation Process for preparation of conductive polymeric composite particles

Also Published As

Publication number Publication date
ATE451125T1 (de) 2009-12-15
ES2336053T3 (es) 2010-04-07
CA2233725A1 (en) 1999-09-30
EP1066057A1 (de) 2001-01-10
JP4674289B2 (ja) 2011-04-20
JP2002509898A (ja) 2002-04-02
CN1191864C (zh) 2005-03-09
RU2225222C2 (ru) 2004-03-10
NZ507383A (en) 2003-10-31
WO1999049897A1 (en) 1999-10-07
US6500930B2 (en) 2002-12-31
AU759595B2 (en) 2003-04-17
US20030125238A1 (en) 2003-07-03
US20020040128A1 (en) 2002-04-04
EP1066057B1 (de) 2009-12-09
CN1301179A (zh) 2001-06-27
AU2918099A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
DE69941775D1 (de) Hämoglobin-polysaccharid-konjugate
DE60004172D1 (de) Gcsf konjugate
DE69830326D1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
EA200200684A1 (ru) Полипептидные композиции, обладающие повышенной стабильностью
MY102878A (en) Starburst conjugates
MXPA05005854A (es) Utilizacion de polisacaridos particulares como mezclas de materiales minerales.
IN2012DN00520A (de)
TR200102342T2 (tr) Paramilon içeren dondurularak kurutulmuş madde, bunun üretimi ve kullanımı.
TR199700358A2 (xx) �nterferon birle�imler.
MY158231A (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2005056572A3 (en) Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
EA199900598A1 (ru) Производные 1-арил- и пиридилпиразола с пестицидными свойствами
YU40700A (sh) Derivati eritropoetina
MX2009006410A (es) Conjugados de polimero-oligonucleotido, proteina y/o peptido.
DE50011039D1 (de) Schwingungsarmer, zweistufiger tauchkolbenverdichter
TW200505941A (en) Modified hemoglobin and methods of making same
EP1003526A4 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendung
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
DE69029396T2 (de) Konjugatimpfstoff für gruppe b-streptococcus
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
WO1999042139A3 (de) Hydroxyethylstärke-konjugate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutische mittel
CA2326715A1 (en) Hemoglobin-polysaccharide conjugates
AU3760795A (en) Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
AU2003285286A1 (en) Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
DK1037642T3 (da) Modificerede polysaccharider med ændret biologisk genkendelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition